Results 131 to 140 of about 22,723 (239)

On the role of RNA binding proteins in polyglutamine diseases: from pathogenesis to therapeutics. [PDF]

Neural Regen Res, 2023
Conceição A, Koppenol R, Nóbrega C.
europepmc   +1 more source

Unexpected cell type-dependent effects of autophagy on polyglutamine aggregation revealed by natural genetic variation in C. elegans. [PDF]

, 2020
BACKGROUND: Monogenic protein aggregation diseases, in addition to cell selectivity, exhibit clinical variation in the age of onset and progression, driven in part by inter-individual genetic variation. While natural genetic variants may pinpoint plastic
Alexander-Floyd, J, Entezari, A A, Gidalevitz, T, Haroon, S, Jaeger, C, Vermulst, M, Ying, M   +6 more
core   +1 more source

Contribution of Glial Cells to Polyglutamine Diseases: Observations from Patients and Mouse Models. [PDF]

Neurotherapeutics, 2023
Cvetanovic M, Gray M.
europepmc   +1 more source

Polyglutamine Flanking Regions in Huntingtin Highlight Key Structural Intermediates Relevant for Molecular Chaperone Interaction and Huntington's Disease Pathogenesis [PDF]

, 2014
Koning Shen, Barbara Calamini, Donald C. Lo, Judith Frydman   +3 more
openalex   +1 more source

A survey of protein interactions and posttranslational modifications that influence the polyglutamine diseases. [PDF]

Front Mol Neurosci, 2022
Johnson SL, Tsou WL, Prifti MV, Harris AL, Todi SV.   +4 more
europepmc   +1 more source

FipoQ/FBXO33, a Cullin‐1‐based ubiquitin ligase complex component modulates ubiquitination and solubility of polyglutamine disease protein [PDF]

, 2019
Zhefan Stephen Chen, Azaria Kam Yan Wong, Tat Cheung Cheng, Alex Chun Koon, Ho Yin Edwin Chan   +4 more
openalex   +1 more source

HSP90 inhibitors stimulate DNAJB4 protein expression through a mechanism involving N6-methyladenosine. [PDF]

, 2019
Small-molecule inhibitors for the 90-kDa heat shock protein (HSP90) have been extensively exploited in preclinical studies for the therapeutic interventions of human diseases accompanied with proteotoxic stress.
Chen, Xuemei, Dai, Xiaoxia, Li, Lin, Miao, Weili, Wang, Yinsheng, Zhao, Yonghui   +5 more
core   +1 more source

Identification of Novel Therapeutic Targets for Polyglutamine Diseases That Target Mitochondrial Fragmentation. [PDF]

Int J Mol Sci, 2021
Traa A, Machiela E, Rudich PD, Soo SK, Senchuk MM, Van Raamsdonk JM.   +5 more
europepmc   +1 more source

DNAzyme Cleavage of CAG Repeat RNA in Polyglutamine Diseases. [PDF]

Neurotherapeutics, 2021
Zhang N, Bewick B, Schultz J, Tiwari A, Krencik R, Zhang A, Adachi K, Xia G, Yun K, Sarkar P, Ashizawa T.   +10 more
europepmc   +1 more source

From Pathways to Targets: Understanding the Mechanisms behind Polyglutamine Disease [PDF]

, 2014
Jonasz Jeremiasz Weber, Anna Sowa, Tina Binder, Jeannette Hübener‐Schmid   +3 more
openalex   +1 more source